NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive(R) to Participate in the 21st Annual International Meeting on Advanced Spine Techniques (IMAST)

SAN DIEGO, CA -- (Marketwired) -- 07/09/14 -- NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce its participation at the 21st International Meeting on Advanced Spine Techniques (IMAST) from Wednesday, July 16 to Friday, July 18, 2014, in booth #6 at the Valencia Convention Centre in Valencia, Spain.

Sponsored by the Scoliosis Research Society, IMAST gathers more than 1,000 world renowned spine surgeons and industry leaders to present and discuss innovative research and advanced spine technologies. The Scoliosis Research Society has gained recognition as one of the world's premier spine societies committed to research and education in the field of spine deformities.

"We are thrilled to have the opportunity to showcase our innovative, procedurally integrated solutions to leading spine surgeons at IMAST," said Pat Miles, NuVasive President of Global Products and Services. "At this year's meeting, we will focus our educational efforts around advanced applications of XLIF® as well as Anterior Column Realignment (ACR™) of the spine."

As an IMAST diamond sponsor, NuVasive is scheduled to participate in the following events:

  • NuVasive Exhibit Booth #6: The NuVasive exhibit booth will feature a number of innovative, minimally disruptive products and procedures, including: XLIF, XLIF ACR, Precept®, Armada®, MAS® PLIF, AttraX® Putty, CoRoent Small Interlock™, NuVasive Helix-Revolution, PCM®, VuePoint® II OCT, Bendini®, and NVM5®.

  • NuVasive® Hands-on Workshops:
    • XLIF for Deformity and Advanced Applications
      Wednesday, July 16th from 17:00-19:00
      Presented by Behrooz Akbarnia, M.D., Luiz Pimenta, M.D., and William Smith, M.D.
    • Anterior Column Realignment (ACR): Techniques to Restore Global Alignment
      Thursday, July 17th from 12:25-13:25
      Presented by Regis Haid, M.D., Christopher Shaffrey, M.D., and Juan Uribe, M.D.

Click here to download the complete IMAST program.

Click here to download the IMAST Mobile and Online application.

About IMAST:

The International Meeting on Advanced Spinal Techniques (IMAST), sponsored by the Scoliosis Research Society, provides an international scientific forum for spine professionals to stay up-to-date on emerging new technologies and techniques. For three days, spine surgeons and other allied health professionals from around the world discuss, debate, and demonstrate recent advances in spine surgery.

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.

NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game-changing technology such as the XLIF Decade™ plate for single-approach fixation through a lateral incision, the PCM® motion-preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and the Armada® posterior fixation system, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedurally integrated solutions that completely redefine and improve upon traditional techniques like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons worldwide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation, and Absolute Responsiveness®.

About Our Products and Procedures

Spine surgeries carry inherent risks and potential complications, which should be discussed between patient and surgeon. Complications vary in severity, including the possibility of death, and can result from surgery in general (e.g., infection or bleeding requiring transfusion), from the approach to the pathology (e.g., vascular, organ or other soft-tissue injury, or injuries to the motor or sensory nerves), spine surgery related complications (e.g., re-operation required for malpositioned hardware or inadequate decompression) and medical related issues (e.g., due to other co-morbidities such as diabetes, heart disease, lung disease, use of steroids, and/or smoking).

Complications can also manifest later in the postoperative period, which may require additional procedures (e.g., delayed wound healing, infection, migration or failure of the implants, fracture or settling of the bone, failed fusion).

The XLIF procedure, like any other surgical procedure, is not without risks. Possible complications include, but are not limited to: persistent pain, infection, muscle weakness, vascular injury (injury of the blood vessels), neurologic (nerve or spinal cord) injury, urinary tract infection, stroke, pneumonia, deep vein thrombosis (clotting), and further progression of existing spinal disease. In general, however, complications are uncommon. A discussion detailing all potential risks of the XLIF procedure, or any procedure, should take place between patient and physician.

It is important to reiterate that planning for spine surgery should include detailed discussion between patient and surgeon concerning potential complications associated with current spine surgery treatment options.

The information provided in this press release is for general educational information only. Information you read in this press release cannot replace the relationship that you have with your healthcare professional. We do not practice medicine or provide medical advice as part of this press release. You should also talk to your healthcare professional for diagnosis and treatment.

NuVasive cautions you that statements included in this press release or during IMAST that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Investor Contact:
Tina Jacobsen
NuVasive, Inc.
Email Contact

Media Contact:
Kristine Simmons
NuVasive, Inc.
Email Contact

Source: NuVasive, Inc.